NYSE:HIMSHealthcare
FDA Pressure Tests Hims And Hers Weight Loss Growth Story
FDA is moving to exclude key GLP-1 drugs from its bulk compounding list, putting pressure on Hims & Hers Health's compounded weight-loss offerings.
Hims & Hers (NYSE:HIMS) is responding by leaning into partnerships for branded GLP-1 medications, including a deal with Novo Nordisk.
The company is also pushing into international markets through acquisitions such as Australian telehealth provider Eucalyptus.
Hims & Hers Health, trading at $26.33, sits at an interesting point in its story. The...